for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Akcea Therapeutics Inc

AKCA.OQ

Latest Trade

18.11USD

Change

-0.02(-0.11%)

Volume

45,592

Today's Range

17.61

 - 

18.17

52 Week Range

13.90

 - 

35.82

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
18.13
Open
18.02
Volume
45,592
3M AVG Volume
5.84
Today's High
18.17
Today's Low
17.61
52 Week High
35.82
52 Week Low
13.90
Shares Out (MIL)
93.03
Market Cap (MIL)
1,686.68
Forward P/E
-36.08
Dividend (Yield %)
--

Next Event

Q3 2019 Akcea Therapeutics Inc Earnings Call

Latest Developments

More

Akcea Announces Damien Mcdevitt As Interim Chief Executive Officer

Akcea Reports Q2 2019 Results

Akcea Therapeutics Reports Q1 Earnings Per Share $0.34

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Akcea Therapeutics Inc

Akcea Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders. The Company's drugs, volanesorsen, AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx and AKCEA-APOCIII-LRx, are all based on antisense technology developed by Ionis Pharmaceuticals, Inc. (Ionis). The Company's volanesorsen drug has completed a Phase III clinical program for the treatment of familial chylomicronemia syndrome (FCS) and is currently in Phase III clinical development for the treatment of familial partial lipodystrophy (FPL). The Company's clinical pipeline contains drugs with the potential to treat inadequately addressed lipid disorders beyond elevated LDL-C that are contributing to the dramatic increase in the incidence of cardiometabolic disease, such as elevated triglycerides, oxidized phospholipids and other lipoproteins, such as lipoprotein(a), or Lp(a).

Industry

Biotechnology & Drugs

Contact Info

22 Boston Wharf Rd Fl 9

+1.617.2070202

http://akceatx.com/

Executive Leadership

Christopher F.O. Gabrieli

Chairman of the Board

Damien McDevitt

Interim Chief Executive Officer, Director

Michael Maclean

Chief Financial Officer

Louis St. L. O'Dea

Chief Medical Officer

Joseph Klein

Director

Key Stats

2.20 mean rating - 5 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.1K

2018

0.1K

2019(E)

0.3K
EPS (USD)

2017

-3.050

2018

-2.740

2019(E)

-0.503
Price To Earnings (TTM)
--
Price To Sales (TTM)
7.67
Price To Book (MRQ)
4.57
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-42.35
Return on Equity (TTM)
-34.80

Latest News

Latest News

EU committee approves Akcea-Ionis drug for rare genetic disease

An advisory committee of the European Medicines Agency (EMA) on Friday recommended conditionally approving a drug from Akcea Therapeutics Inc and Ionis Pharmaceuticals Inc that aims to treat a rare genetic disease that causes fat accumulation in the blood.

BRIEF-Akcea Therapeutics Says Co Will Receive A $150 Mln License Fee That Will Be Split Equally With Ionis

* AKCEA-APO(A)-LRX ADVANCES AS LEADING PHARMACEUTICAL COMPANY EXERCISES OPTION TO LICENSE

Akcea Therapeutics genetic disease treatment gets FDA approval

Akcea Therapeutics Inc said on Friday its treatment, developed along with Ionis Pharmaceuticals , which targets a rare genetic disease was approved by the U.S. Food and Drug Administration.

Akcea Therapeutics to cut about 10 percent of workforce

Akcea Therapeutics Inc said on Thursday it planned to cut its workforce by about 10 percent after the U.S. health regulator declined to approve its Waylivra drug for treating a genetic disease that causes fat accumulation in blood.

Akcea Therapeutics to cut about 10 pct of workforce

Akcea Therapeutics Inc said on Thursday it planned to cut its workforce by about 10 percent after the U.S. health regulator declined to approve its Waylivra drug for treating a genetic disease that causes fat accumulation in blood.

FDA declines to approve Akcea-Ionis genetic disease drug

The U.S. Food and Drug Administration on Monday declined to approve a drug from Akcea Therapeutics Inc and Ionis Pharmaceuticals that aims to treat a genetic disease that causes fat accumulation in the blood.

U.S. FDA declines to approve Akcea/Ionis genetic disease drug

The U.S. Food and Drug Administration on Monday declined to approve a drug from Akcea Therapeutics Inc and Ionis Pharmaceuticals that aims to treat a genetic disease which causes fat accumulation in the blood.

BRIEF-Akcea Posts Q4 Loss Per Share $0.35

* AKCEA REPORTS FINANCIAL RESULTS AND HIGHLIGHTS FOR FOURTH QUARTER AND YEAR END 2017

BRIEF-Akcea Completes Enrollment In Phase 2B Study Of Akcea-Apo(A)-LRx

* AKCEA COMPLETES ENROLLMENT IN PHASE 2B STUDY OF AKCEA-APO(A)-LRX Source text for Eikon: Further company coverage:

BRIEF-Akcea and Ionis announce acceptance of marketing applications in U.S., EU and Canada for Volanesorsen

* Akcea and Ionis announce acceptance of marketing applications in U.S., EU and Canada for Volanesorsen for the treatment of FCS

BRIEF-Akcea Therapeutics Q3 loss per share $0.27

* Q3 earnings per share view $-0.19, revenue view $11.9 million -- Thomson Reuters I/B/E/S Source text for Eikon: Further company coverage:

BRIEF-AKCEA PRESENTS DATA DEMONSTRATING SIGNIFICANT BURDEN OF ILLNESS IN FAMILIAL CHYLOMICRONEMIA SYNDROME

* AKCEA PRESENTS DATA DEMONSTRATING SIGNIFICANT BURDEN OF ILLNESS IN FAMILIAL CHYLOMICRONEMIA SYNDROME Source text for Eikon: Further company coverage:

BRIEF-Akcea and Ionis announce filing of new drug submission for Volanesorsen to Health Canada

* Akcea and Ionis announce filing of new drug submission for volanesorsen to Health Canada

BRIEF-Akcea Therapeutics establishes Canadian subsidiary

* Akcea Therapeutics Inc - Establishment of Ottawa-based Canadian unit and appointment of Jared Rhines as general manager for Akcea Therapeutics Canada Source text for Eikon: Further company coverage:

BRIEF-Akcea Therapeutics says co announced Mike Maclean joins as CFO, effective August 31

* Akcea Therapeutics says on Sept 5, co announced Mike Maclean joined company as Chief Financial Officer, effective August 31- SEC filing Source text for Eikon: [http://bit.ly/2eIZHLj] Further company coverage:

BRIEF-Akcea and Ionis submits New Drug Application for volanesorsen to FDA

* Akcea and Ionis announce submission of new drug application for volanesorsen to the U.S. FDA

BRIEF-Akcea Q2 loss per share $0.41

* Akcea reports financial results and highlights for second quarter 2017

BRIEF-Akcea, Ionis announce submission of marketing authorization application

* Akcea and Ionis announce submission of marketing authorization application for volanesorsen to the European Medicines Agency

BRIEF-Novartis reports 9.7 pct passive stake in Akcea Therapeutics as of July 19

* Novartis Pharma AG reports 9.7 percent passive stake in Akcea Therapeutics Inc as of July 19, 2017 - SEC filing Source text for Eikon: Further company coverage:

BRIEF-Akcea Therapeutics Inc shares open at $8.13 in debut vs IPO price of $8/share

* Akcea Therapeutics Inc shares open at $8.13 in debut on the NASDAQ versus IPO price of $8.00 per share

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up